Zoryve cream, also known as roflumilast topical foam, is a prescription medication used to treat plaque psoriasis [1]. It works by reducing inflammation associated with the condition [1].
How does Zoryve cream work?
Zoryve cream contains roflumilast, a phosphodiesterase 4 (PDE4) inhibitor [1]. PDE4 is an enzyme found in skin cells that plays a role in inflammation. By inhibiting PDE4, roflumilast helps to decrease the production of inflammatory molecules in the skin, thereby reducing the redness, scaling, and thickening characteristic of psoriasis [1].
What type of psoriasis is Zoryve cream approved for?
Zoryve cream is approved for the topical treatment of plaque psoriasis in adults and children 12 years of age and older [1]. Plaque psoriasis is the most common form of the condition, presenting as raised, red, scaly patches [2].
How is Zoryve cream applied?
Zoryve cream is applied once daily to affected areas of the skin [1]. Patients should follow their healthcare provider's instructions for application and duration of treatment [1].
What are the potential side effects of Zoryve cream?
The most common side effects reported in clinical trials include diarrhea, headache, insomnia, nausea, and upper respiratory tract infection [1]. Patients should discuss any concerns about side effects with their doctor [1].
When did Zoryve cream become available?
Zoryve cream was approved by the U.S. Food and Drug Administration (FDA) in July 2022 [1].
Are there other topical treatments for psoriasis?
Yes, various other topical treatments are available for psoriasis, including corticosteroids, vitamin D analogs, retinoids, and calcineurin inhibitors. Zoryve cream offers a different mechanism of action as a PDE4 inhibitor [3].
What is the patent status of Zoryve cream?
Information regarding the patent status and exclusivity of Zoryve cream can be found on resources like DrugPatentWatch.com [4].